Food-grade bacteria expressing elafin protect against inflammation and restore colon homeostasis

Science Translational Medicine

Volumn 4, Issue 158, 2012, Pages

  Motta, Jean Paul ^a,b,c   Bermúdez Humarán, Luis G ^d   Deraison, Céline ^a,b,c   Martin, Laurence ^a,b,c   Rolland, Corinne ^a,b,c   Rousset, Perrine ^a,b,c   Boue, Jérôme ^a,b,c   Dietrich, Gilles ^a,b,c   Chapman, Kevin ^e   Kharrat, Pascale ^d   Vinel, Jean Pierre ^c,f   Alric, Laurent ^c,f   Mas, Emmanuel ^a,b,c,g   Sallenave, Jean Michel ^a,h,i   Langella, Philippe ^d   Vergnolle, Nathalie ^a,b,c,e  

^a INSERM   (France)

^b CNRS   (France)

^c France   (France)

^d CEMAGREF   (France)

^e UNIVERSITY OF CALGARY   (Canada)

^f CHU PURPAN   (France)

^g HÔPITAL DES ENFANTS   (France)

^h INSTITUT PASTEUR   (France)

ⁱ UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CYTOKINE; ELAFIN; PROTEINASE INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BACTERIAL STRAIN; CELL CULTURE; COLITIS; COLON; CONTROLLED STUDY; CYTOKINE RELEASE; ELASTOLYSIS; ENTERITIS; ENTEROPATHY; GENE EXPRESSION; GENETIC ENGINEERING; HUMAN; HUMAN TISSUE; IN VITRO STUDY; INFLAMMATION; INTESTINE EPITHELIUM CELL; INTESTINE MUCOSA; INTESTINE MUCOSA PERMEABILITY; LACTIC ACID BACTERIUM; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRAL GENE THERAPY;

ANIMALS; BACTERIA; COLON; ELAFIN; HUMANS; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; MICE;

EID: 84868288692     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3004212     Document Type: Article

References (33)

1. N. Vergnolle, Clinical relevance of proteinase activated receptors (pars) in the gut. Gut 54, 867-874 (2005). (Pubitemid 40732107)
2. J. P. Motta, L. Magne, D. Descamps, C. Rolland, C. Squarzoni-Dale, P. Rousset, L. Martin, N. Cenac, V. Balloy, M. Huerre, L. F. Fröhlich, D. Jenne, J. Wartelle, A. Belaaouaj, E. Mas, J. P. Vinel, L. Alric, M. Chignard, N. Vergnolle, J. M. Sallenave, Modifying the protease, antiprotease pattern by elafin overexpression protects mice from colitis. Gastroenterology 140, 1272-1282 (2011).
3. N. Vergnolle, Protease-activated receptors as drug targets in inflammation and pain. Pharmacol. Ther. 123, 292-309 (2009).
4. N. Vergnolle, Review article: Proteinase-activated receptors -Novel signals for gastrointestinal pathophysiology. Aliment. Pharmacol. Ther. 14, 257-266 (2000). (Pubitemid 30145312)
5. N. Cenac, C. N. Andrews, M. Holzhausen, K. Chapman, G. Cottrell, P. Andrade-Gordon, M. Steinhoff, G. Barbara, P. Beck, N. W. Bunnett, K. A. Sharkey, J. G. Ferraz, E. Shaffer, N. Vergnolle, Role for protease activity in visceral pain in irritable bowel syndrome. J. Clin. Invest. 117, 636-647 (2007). (Pubitemid 46348522)
6. M. Schmid, K. Fellermann, P. Fritz, O. Wiedow, E. F. Stange, J. Wehkamp, Attenuated induction of epithelial and leukocyte serine antiproteases elafin and secretory leukocyte protease inhibitor in Crohn's disease. J. Leukoc. Biol. 81, 907-915 (2007). (Pubitemid 46495639)
7. J. M. Sallenave, Secretory leukocyte protease inhibitor and elafin/trappin-2: Versatile mucosal antimicrobials and regulators of immunity. Am. J. Respir. Cell Mol. Biol. 42, 635-643 (2010).
8. L. Shaw, O. Wiedow, Therapeutic potential of human elafin. Biochem. Soc. Trans. 39, 1450-1454 (2011).
9. L. Steidler, W. Hans, L. Schotte, S. Neirynck, F. Obermeier, W. Falk, W. Fiers, E. Remaut, Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 289, 1352-1355 (2000). (Pubitemid 30656052)
10. L. G. Bermúdez-Humarán, N. G. Cortes-Perez, F. Lefèvre, V. Guimãraes, S. Rabot, J. M. Alcocer-Gonzalez, J. J. Gratadoux, C. Rodriguez-Padilla, R. S. Tamez-Guerra, G. Corthier, A. Gruss, P. Langella, A novel mucosal vaccine based on live lactococci expressing E7 antigen and IL-12 induces systemic and mucosal immune responses and protects mice against human papillomavirus type 16-induced tumors. J. Immunol. 175, 7297-7302 (2005). (Pubitemid 41713425)
11. C. Daniel, Y. Roussel, M. Kleerebezem, B. Pot, Recombinant lactic acid bacteria as mucosal biotherapeutic agents. Trends Biotechnol. 29, 499-508 (2011).
12. T. Rochat, L. Bermúdez-Humarán, J. J. Gratadoux, C. Fourage, C. Hoebler, G. Corthier, P. Langella, Anti-inflammatory effects of Lactobacillus casei BL23 producing or not a manganese-dependant catalase on DSS-induced colitis in mice. Microb. Cell Fact. 6, 22 (2007).
13. L. Watterlot, T. Rochat, H. Sokol, C. Cherbuy, I. Bouloufa, F. Lefèvre, J. J. Gratadoux, E. Honvo-Hueto, S. Chilmonczyk, S. Blugeon, G. Corthier, P. Langella, L. G. Bermúdez-Humarán, Intragastric administration of a superoxide dismutase-producing recombinant Lactobacillus casei BL23 strain attenuates DSS colitis in mice. Int. J. Food Microbiol. 144, 35-41 (2010).
14. E. Hyun, P. Andrade-Gordon, M. Steinhoff, N. Vergnolle, Protease-activated receptor-2 activation: A major actor in intestinal inflammation. Gut 57, 1222-1229 (2008).
15. F. Powrie, R. Correa-Oliveira, S. Mauze, R. L. Coffman, Regulatory interactions between CD45RBhigh and CD45RBlow CD4+ T cells are important for the balance between protective and pathogenic cell-mediated immunity. J. Exp. Med. 179, 589-600 (1994).
16. F. Shanahan, S. M. Collins, Pharmabiotic manipulation of the microbiota in gastrointestinal disorders, from rationale to reality. Gastroenterol. Clin. North Am. 39, 721-726 (2010).
17. J. M. Sallenave, A. P. Ryle, Purification and characterization of elastase-specific inhibitor. Sequence homology with mucus proteinase inhibitor. Biol. Chem. Hoppe Seyler 372, 13-21 (1991).
18. O. Wiedow, J. M. Schröder, H. Gregory, J. A. Young, E. Christophers, Elafin: An elastasespecific inhibitor of human skin. Purification, characterization, and complete amino acid sequence. J. Biol. Chem. 265, 14791-14795 (1990).
19. N. Guyot, M. L. Zani, M. C. Maurel, S. Dallet-Choisy, T. Moreau, Elafin and its precursor trappin-2 still inhibit neutrophil serine proteinases when they are covalently bound to extracellular matrix proteins by tissue transglutaminase. Biochemistry 44, 15610-15618 (2005). (Pubitemid 41706146)
20. M. W. Butler, I. Robertson, C. M. Greene, S. J. O'Neill, C. C. Taggart, N. G. McElvaney, Elafin prevents lipopolysaccharide-induced AP-1 and NF-kB activation via an effect on the ubiquitinproteasome pathway. J. Biol. Chem. 281, 34730-34735 (2006). (Pubitemid 46036512)
21. P. A. Henriksen, M. Hitt, Z. Xing, J. Wang, C. Haslett, R. A. Riemersma, D. J. Webb, Y. V. Kotelevtsev, J. M. Sallenave, Adenoviral gene delivery of elafin and secretory leukocyte protease inhibitor attenuates NF-kB-dependent inflammatory responses of human endothelial cells and macrophages to atherogenic stimuli. J. Immunol. 172, 4535-4544 (2004). (Pubitemid 38375271)
22. H. Braat, P. Rottiers, D. W. Hommes, N. Huyghebaert, E. Remaut, J. P. Remon, S. J. van Deventer, S. Neirynck, M. P. Peppelenbosch, L. Steidler, A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clin. Gastroenterol. Hepatol. 4, 754-759 (2006). (Pubitemid 43841860)
23. J. Grimoud, H. Durand, S. de Souza, P. Monsan, F. Ouarné, V. Theodorou, C. Roques, In vitro screening of probiotics and synbiotics according to anti-inflammatory and anti-proliferative effects. Int. J. Food Microbiol. 144, 42-50 (2010).
24. N. A. Nagalingam, S. V. Lynch, Role of the microbiota in inflammatory bowel diseases. Inflamm. Bowel Dis. 18, 968-984 (2012).
25. L. Steidler, P. Rottiers, Therapeutic drug delivery by genetically modified Lactococcus lactis. Ann. N. Y. Acad. Sci. 1072, 176-186 (2006). (Pubitemid 44448451)
26. L. Steidler, S. Neirynck, N. Huyghebaert, V. Snoeck, A. Vermeire, B. Goddeeris, E. Cox, J. P. Remon, E. Remaut, Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10. Nat. Biotechnol. 21, 785-789 (2003). (Pubitemid 36791397)
27. A. Chogle, H. F. Bu, X. Wang, J. B. Brown, P. M. Chou, X. D. Tan, Milk fat globule-EGF factor 8 is a critical protein for healing of dextran sodium sulfate-induced acute colitis in mice. Mol. Med. 17, 502-507 (2011).
28. J. M. Sallenave, Z. Xing, A. J. Simpson, F. L. Graham, J. Gauldie, Adenovirus-mediated expression of an elastase-specific inhibitor (elafin): A comparison of different promoters. Gene Ther. 5, 352-360 (1998). (Pubitemid 28138241)
29. C. Nieto, M. Espinosa, Construction of the mobilizable plasmid pMV158GFP, a derivative of pMV158 that carries the gene encoding the green fluorescent protein. Plasmid 49, 281-285 (2003). (Pubitemid 36561418)
30. N. Cenac, L. Cellars, M. Steinhoff, P. Andrade-Gordon, M. D. Hollenberg, J. L. Wallace, S. Fiorucci, N. Vergnolle, Proteinase-activated receptor-1 is an anti-inflammatory signal for colitis mediated by a type 2 immune response. Inflamm. Bowel Dis. 11, 792-798 (2005). (Pubitemid 41368266)
31. N. Cenac, A. M. Coelho, C. Nguyen, S. Compton, P. Andrade-Gordon, W. K. MacNaughton, J. L. Wallace, M. D. Hollenberg, N. W. Bunnett, R. Garcia-Villar, L. Bueno, N. Vergnolle, Induction of intestinal inflammation in mouse by activation of proteinase-activated receptor-2. Am. J. Pathol. 161, 1903-1915 (2002). (Pubitemid 35265547)
32. C. Bonnart, C. Deraison, M. Lacroix, Y. Uchida, C. Besson, A. Robin, A. Briot, M. Gonthier, L. Lamant, P. Dubus, B. Monsarrat, A. Hovnanian, Elastase 2 is expressed in human and mouse epidermis and impairs skin barrier function in Netherton syndrome through filaggrin and lipid misprocessing. J. Clin. Invest. 120, 871-882 (2010).
33. A. C. Chin, W. Y. Lee, A. Nusrat, N. Vergnolle, C. A. Parkos, Neutrophil-mediated activation of epithelial protease-activated receptors-1 and -2 regulates barrier function and transepithelial migration. J. Immunol. 181, 5702-5710 (2008).